A. The proportion of patients with schizophrenia and bipolar disorder on long-term disability is about the same as that of patients with other chronic illnesses B. Patients with bipolar disorder die earlier than the general population, mostly of suicide C. Weight gain/obesity, diabetes, and cardiovascular disease are common comorbidities of both illnesses, as well as side effects of the medications used to treat them D. When looking at the brains of patients with schizophrenia and bipolar disorder, increases in gray matter are generally seen secondary to neurodegeneration E. Unsure

A. Clinicians tend to over-estimate adherence to medications B. Medication nonadherence leads to a poorer prognosis C. Substance abuse, high intensity of symptoms, and cognitive impairment are general predictors of nonadherence D. Generally, adherence rates are around 60%–70% in schizophrenia and bipolar disorder E. Unsure

A. The reason the drug concentrations remain elevated for an extended time is because the dose is really large B. Some agents require an oral overlap during the initiation phase of LAIs; other agents require a higher dose or initiation product at the start to help keep concentrations up C. The use of insoluble salt formulations is possible because they are in suspensions, which helps the drug dissolve after injection D. It is difficult to track medication adherence with LAIs E. Unsure